Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Open Access
- 18 July 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-10
Abstract
There is a need for clinically useful biomarkers of disease activity in clinically isolated syndrome (CIS) and relapsing remitting MS (RRMS). The aim of this study was to assess the correlation between neurofilament light chain (NFL) in cerebrospinal fluid (CSF) and serum and the relationship between NFL and other biomarkers, subsequent disease activity, and brain volume loss in CIS and RRMS. A panel of neurodegenerative and neuroinflammatory markers were analyzed in repeated CSF samples from 41 patients with CIS or RRMS in a prospective longitudinal cohort study and from 22 healthy controls. NFL in serum was analyzed using a single-molecule array (Simoa) method. “No evidence of disease activity-3” (NEDA-3) status and brain volume (brain parenchymal fraction calculated using SyMRI®) were recorded during 4 years of follow-up. NFL levels in CSF and serum correlated significantly (all samples, n = 63, r 0.74, p < 0.001), but CSF-NFL showed an overall stronger association profile with NEDA-3 status, new T2 lesions, and brain volume loss. CSF-NFL was associated with both new T2 lesions and brain volume loss during follow-up, whereas CSF-CHI3L1 was associated mainly with brain volume loss and CXCL1, CXCL10, CXCL13, CCL22, and MMP-9 were associated mainly with new T2 lesions. Serum and CSF levels of NFL correlate, but CSF-NFL predicts and reflects disease activity better than S-NFL. CSF-NFL levels are associated with both new T2 lesions and brain volume loss. Our findings further add to the accumulating evidence that CSF-NFL is a clinically useful biomarker in CIS and RRMS and should be considered in the expanding NEDA concept. CSF-CXCL10 and CSF-CSF-CHI3L1 are potential markers of disease activity and brain volume loss, respectively.Keywords
Funding Information
- Vetenskapsrådet (K2013-61X-22310-01-4)
This publication has 38 references indexed in Scilit:
- Brain atrophy and lesion load predict long term disability in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Automated Determination of Brain Parenchymal Fraction in Multiple SclerosisAmerican Journal of Neuroradiology, 2012
- Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis (P03.055)Neurology, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabAnnals of Neurology, 2010
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesNeurology, 2010
- Neurofilament light as a prognostic marker in multiple sclerosisMultiple Sclerosis Journal, 2010
- Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MSNeurology, 2009
- Rapid magnetic resonance quantification on the brain: Optimization for clinical usageMagnetic Resonance in Medicine, 2008
- A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adultsJournal of Neuroscience Methods, 1994